Akebia Therapeutics (AKBA) Tax Provisions (2018 - 2026)

Akebia Therapeutics (AKBA) reported Tax Provisions of $126000.0 for Q1 2026, down 87.51% quarter-over-quarter from $1.0 million in Q4 2025.

Akebia Therapeutics (AKBA) Tax Provisions (2018 - 2026) Analysis & Trends

Akebia Therapeutics (AKBA) has 4 years of Tax Provisions data on file, last reported at $126000.0 in Q1 2026.

Tax Provisions for Q1 2026 came in at $126000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (changed N/A YoY), and the FY2025 annual result was $1.6 million, changed N/A from the prior year.
Tax Provisions slipped to $126000.0 in Q1 2026 per AKBA's latest filing, from $1.0 million in the prior quarter.
Over five years, Tax Provisions peaked at $1.0 million in Q4 2025 and troughed at $126000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	67.00 Mn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	157.00 Mn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	43.40 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-3.57 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	48.90 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	30.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	4.60 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-9.44 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	37.99 Mn
10	Akebia Therapeutics	243.23 Mn	80.63 Mn	41.25 Mn	126,000.00

Download Data